Oppenheimer analyst Leah Rush Cann reiterated an Outperform rating and $166 price target on Celgene (NASDAQ: CELG) following a neurologist ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE